Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial

Abstract

BACKGROUND: 4CMenB is immunogenic in infants and toddlers. We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24months and characterised the antibody response to a fifth dose administered at 4years of age. METHODS: A phase 3, open label, multi-centre extension to a randomised controlled trial conducted in four countries (number of centres): Czech Republic (nineteen), …

Authors

Iro MA; Snape MD; Voysey M; Jawad S; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R

Journal

Vaccine, Vol. 35, No. 2, pp. 395–402

Publisher

Elsevier

Publication Date

January 2017

DOI

10.1016/j.vaccine.2016.11.009

ISSN

0264-410X

Associated Experts

Adefowope Odueyungbo

Assistant Professor (Part-Time), Faculty of Health Sciences

Visit profile

Labels